Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Harmony Biosciences Holdings, Inc. - Common Stock
(NQ:
HRMY
)
28.11
+0.49 (+1.77%)
Streaming Delayed Price
Updated: 9:38 AM EDT, Apr 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Harmony Biosciences Holdings, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
April 07, 2026
The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most...
Via
Finterra
Topics
Economy
Intellectual Property
Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
April 06, 2026
On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total...
Via
MarketMinute
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
April 06, 2026
Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has...
Via
MarketMinute
Topics
Intellectual Property
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Case for Quality at a Discount
↗
March 13, 2026
Via
Chartmill
Harmony Biosciences (HRMY) Earnings Transcript
↗
February 24, 2026
Harmony Biosciences (HRMY) Earnings Transcript
Via
The Motley Fool
Harmony Biosciences Holdings (NASDAQ:HRMY) Reports Q4 2025 Revenue In Line, Earnings Miss Amid Pipeline Investment
↗
February 24, 2026
Via
Chartmill
Topics
Earnings
Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Compelling Value and Growth Pick
↗
February 20, 2026
Via
Chartmill
HRMY Stock Rises On Fresh FDA Approval For Wakix Tablets In Children But Wall Street Eyes Further Rally
↗
February 17, 2026
The FDA has approved Harmony’s Wakix tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.
Via
Stocktwits
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup
↗
February 17, 2026
Via
Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Prime GARP Investment
↗
February 13, 2026
Via
Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Combines Strong Fundamentals with Bullish Technical Setup
↗
January 26, 2026
Via
Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Embodies the Affordable Growth Strategy
↗
January 09, 2026
Via
Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value and Quality Investment Case
↗
January 06, 2026
Via
Chartmill
Harmony Biosciences Chief Financial Officer Sells Shares Again After Previous Exit From Company Equity
↗
February 01, 2026
This top executive at Harmony Biosciences previous sold all of his direct shares in the company in early January 2026. But towards the end of the month, some options and restricted stock units vested,...
Via
The Motley Fool
Topics
Regulatory Compliance
Harmony Biosciences' CFO Sells All of His Insider Shares, Worth $752,800
↗
January 31, 2026
This bioscience company has had promising financials, yet one of its top executives exited his entire direct equity ownership in mid-January 2026.
Via
The Motley Fool
Topics
Regulatory Compliance
Harmony Biosciences' CFO Sells All of Her Insider Shares, Worth $752,800
↗
January 31, 2026
This bioscience company has had promising financials, yet one of its top executives exited her entire direct equity ownership in mid-January 2026.
Via
The Motley Fool
Topics
Regulatory Compliance
How Harmony Biosciences Can Prove Its Skeptics Wrong
↗
January 28, 2026
The biotech company is looking for multiple successes in the coming years.
Via
The Motley Fool
Topics
Intellectual Property
Earnings Scheduled For November 4, 2025
↗
November 04, 2025
Via
Benzinga
Earnings Preview For Harmony Biosciences
↗
November 03, 2025
Via
Benzinga
Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial?
↗
October 23, 2025
Via
Stocktwits
Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed?
↗
January 27, 2026
Some investors haven't gotten answers to their questions about the biotech stock's past and future.
Via
The Motley Fool
Topics
Initial Public Offering
Intellectual Property
I Was Shocked to Find This Value-Priced Biotech Growth Stock
↗
January 26, 2026
But deciding if it's a good buy takes a little more looking.
Via
The Motley Fool
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
December 30, 2025
As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three...
Via
MarketMinute
Topics
ETFs
Economy
World Trade
Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Prime Growth at a Reasonable Price (GARP) Candidate
↗
December 18, 2025
Harmony Biosciences (HRMY) exemplifies Growth at a Reasonable Price (GARP) with strong sales growth, robust profitability, and a solid financial base, all at a compelling valuation.
Via
Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Case
↗
December 12, 2025
Harmony Biosciences (HRMY) presents a classic value investing case with strong profitability, a healthy balance sheet, and solid growth—all at a compellingly low valuation.
Via
Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Case for Growth at a Reasonable Price
↗
November 26, 2025
Harmony Biosciences (HRMY) is a top GARP stock with strong growth, stellar profitability, and a surprisingly cheap valuation. A compelling growth at a reasonable price pick.
Via
Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Appears Undervalued with Strong Fundamentals
↗
November 15, 2025
Harmony Biosciences (HRMY) appears undervalued with a low P/E ratio, strong profitability, and impressive growth, suggesting a potential market opportunity.
Via
Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Beats Q3 2025 Estimates Despite Muted Market Reaction
↗
November 04, 2025
Harmony Biosciences Q3 2025 earnings beat estimates with strong WAKIX growth. Despite the beat, stock dipped slightly in pre-market trading.
Via
Chartmill
Topics
Earnings
Harmony Biosciences Holdings (NASDAQ:HRMY): A Prime GARP Investment with Strong Growth and a Reasonable Price
↗
October 29, 2025
Harmony Biosciences (HRMY) offers strong growth at a reasonable price. With high EPS growth, robust profitability, and a low P/E ratio, it's a top GARP stock.
Via
Chartmill
Q3 2025 Earnings Season: A Market Navigating AI's Ascent Amidst Economic Shifts
October 23, 2025
The curtain has largely fallen on the Q3 2025 earnings season, revealing a financial landscape characterized by robust corporate performance, particularly in the technology and financial sectors,...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Fraud
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
